PURPOSE: To test whether radiation-induced elevations of transforming growth factor-beta1 (TGF-beta1) during radiation therapy (RT) correlate with radiation-induced lung toxicity (RILT) in patients with non-small-cell lung cancer (NSCLC) and to evaluate the ability of mean lung dose (MLD) to improve the predictive power. METHODS AND MATERIALS: Eligible patients included those with Stage I-III NSCLC treated with RT with or without chemotherapy. Platelet-poor plasma was obtained pre-RT and at 4-5 weeks (40-50 Gy) during RT. TGF-beta1 was measured using an enzyme-linked immunosorbent assay. The primary endpoint was > or = Grade 2 RILT. Mann-Whitney U test, logistic regression, and chi-square were used for statistical analysis. RESULTS: A total of 165 patients were enrolled in this study. The median radiation dose was 60 Gy, and the median MLD was 15.3 Gy. Twenty-nine patients (17.6%) experienced RILT. The incidence of RILT was 46.2% in patients with a TGF-beta1 ratio > 1 vs. 7.9% in patients with a TGF-beta1 ratio < or = 1 (p < 0.001), and it was 42.9% if MLD > 20 Gy vs. 17.4% if MLD < or = 20 Gy (p = 0.024). The incidence was 4.3% in patients with a TGF-beta1 ratio < or = 1 and MLD < or = 20 Gy, 47.4% in those with a TGF-beta1 ratio >1 or MLD > 20 Gy, and 66.7% in those with a TGF-beta1 ratio >1 and MLD > 20 Gy (p < 0.001). CONCLUSIONS: Radiation-induced elevation of plasma TGF-beta1 level during RT is predictive of RILT. The combination of TGF- beta1 and MLD may help stratify the patients for their risk of RILT.
PURPOSE: To test whether radiation-induced elevations of transforming growth factor-beta1 (TGF-beta1) during radiation therapy (RT) correlate with radiation-induced lung toxicity (RILT) in patients with non-small-cell lung cancer (NSCLC) and to evaluate the ability of mean lung dose (MLD) to improve the predictive power. METHODS AND MATERIALS: Eligible patients included those with Stage I-III NSCLC treated with RT with or without chemotherapy. Platelet-poor plasma was obtained pre-RT and at 4-5 weeks (40-50 Gy) during RT. TGF-beta1 was measured using an enzyme-linked immunosorbent assay. The primary endpoint was > or = Grade 2 RILT. Mann-Whitney U test, logistic regression, and chi-square were used for statistical analysis. RESULTS: A total of 165 patients were enrolled in this study. The median radiation dose was 60 Gy, and the median MLD was 15.3 Gy. Twenty-nine patients (17.6%) experienced RILT. The incidence of RILT was 46.2% in patients with a TGF-beta1 ratio > 1 vs. 7.9% in patients with a TGF-beta1 ratio < or = 1 (p < 0.001), and it was 42.9% if MLD > 20 Gy vs. 17.4% if MLD < or = 20 Gy (p = 0.024). The incidence was 4.3% in patients with a TGF-beta1 ratio < or = 1 and MLD < or = 20 Gy, 47.4% in those with a TGF-beta1 ratio >1 or MLD > 20 Gy, and 66.7% in those with a TGF-beta1 ratio >1 and MLD > 20 Gy (p < 0.001). CONCLUSIONS: Radiation-induced elevation of plasma TGF-beta1 level during RT is predictive of RILT. The combination of TGF- beta1 and MLD may help stratify the patients for their risk of RILT.
Authors: Søren M Bentzen; Matthew Parliament; Joseph O Deasy; Adam Dicker; Walter J Curran; Jacqueline P Williams; Barry S Rosenstein Journal: Int J Radiat Oncol Biol Phys Date: 2010-03-01 Impact factor: 7.038
Authors: Peter G Hawkins; Philip S Boonstra; Stephen T Hobson; Jason W D Hearn; James A Hayman; Randall K Ten Haken; Martha M Matuszak; Paul Stanton; Gregory P Kalemkerian; Nithya Ramnath; Theodore S Lawrence; Matthew J Schipper; Feng-Ming Spring Kong; Shruti Jolly Journal: Radiother Oncol Date: 2017-09-23 Impact factor: 6.280
Authors: J Joshua Smith; Isaac Wasserman; Sarah A Milgrom; Oliver S Chow; Chin-Tung Chen; Sujata Patil; Karyn A Goodman; Julio Garcia-Aguilar Journal: Int J Radiat Oncol Biol Phys Date: 2016-12-18 Impact factor: 7.038
Authors: Jianxin Xue; Xin Li; You Lu; Lu Gan; Lin Zhou; Yongsheng Wang; Jie Lan; Shurui Liu; Lan Sun; Li Jia; Xianming Mo; Jian Li Journal: Mol Ther Date: 2012-11-13 Impact factor: 11.454
Authors: Shuanghu Tiger Yuan; Vicki L Ellingrod; Matthew Schipper; Kathleen A Stringer; Xuwei Cai; James A Hayman; Jinming Yu; Theodore S Lawrence; Feng-Ming Spring Kong Journal: J Thorac Oncol Date: 2013-02 Impact factor: 15.609